Nordic pharma Navamedic launches copies of Zyprexa, CellCept; U.S. asthma spending hits $2.5B;

@FiercePharma: Sen. Kohl introduces drug-spending bill. Includes applying Medicaid rebates to Medicare Part B to save up to $44B. Report | Follow @FiercePharma

> Aiming to break the top 5 Nordic generics suppliers, Navamedic has launched its first two copycat products: its version of Eli Lilly's ($LLY) antipsychotic Zyprexa and a copycat form of Roche's organ transplant drug CellCept. News

> An interim analysis found Merck's ($MRK) Isentress outperformed efavirenz in HIV treatment cocktail, measured by the percentage of patients maintaining undetectable virus levels. Merck release

> U.S. spending on asthma drugs quadrupled to $2.5 billion in the decade ending in 2008, as the percentage of children using meds for the condition doubled to 58%. Story

> The U.K.'s cost-effectiveness watchdog backed broader use of Roche's RoActemra in arthritis patients. Article

> European regulators are working on guidelines for animal-derived pharma ingredients to cut the risk of viral contamination. Report

> Amag Pharmaceuticals ($AMAG), which makes the anemia drug Feraheme, asked investors to support its $179 million takeover bid for Allos Therapeutics, despite opposition from MSMB Capital Management. Story

> United Therapeutics is selling $250 million worth of senior notes to finance its stock repurchasing plan. Piece

> CooperVision says it's working to wrap up a recall of 600,000 Avaira Toric contact lenses, spurred by complaints of severe eye pain in users. Report

Biotech News

@FierceBiotech:  Amgen signals looming restructuring of R&D operations. News | Follow @FierceBiotech

@ JohnCFierce: Just off the phone with Vertex's Peter Mueller. Asked him about his thoughts on early-stage development. He laughed and turned on the fire hose of ideas. This is going to be a fun discussion next Wednesday. | Follow @JohnCFierce

@RyanMFierce:  After reading @FierceMedDev's 5 emerging medtech firms report, a Fierce 15 in medical devices makes even more sense. Report | Follow @RyanMFierce

> Anadys gets a boost from positive PhIIb hep C study. Article

> Amgen signals looming restructuring of R&D operations. News

Vaccines News

> Michael J. Fox Foundation bankrolls AFFiRiS Parkinson's vaccine. Article 

> CA law lets tweens make HPV vaccination decisions. News 

> Inovio, VGX ink hep B and C vaccine deal. Item

> HepB vax Heplisav posts positive Ph3 data. Story

> Coridon HSV-2 vaccine shows 100% efficacy. Report

Manufacturing News

> Pain patch maker warned by FDA over validation reporting. Item 

> Genzyme's Ireland site expanded. Article 

> Teva walloped $163M in hepC ruling, doc 'unfit' for trial. Report 

> China assesses illegal drug activities. Story 

> Ex-Genzyme ops chief joins board at bio start-up. News

> Survey: Disposables adoption stymied by lack of standards. Article

And Finally... Blame it on the Black Death: Gene sequencing finds the bacteria is an ancestor of all modern plagues. More

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.